Zimmer Biomet Holdings Inc (ZBH) (Q3 2026) Earnings Call Highlights: Guidance Raised as Hips
Zimmer Biomet (ZBH) reported Q3 2026 earnings, raising guidance despite a 2.6% decline in knee business due to sales force transition and competitive pressure. Adjusted operating margin fell 140 basis points to 25.1%, and gross margin decreased 90 basis points to 71.7%. CEO Ivan Tornos highlighted sustainable growth in hips and S.E.T. areas, but acknowledged underperformance in knees. China headwinds and sales force disruption pose risks.
How this was made

The 30-second read
Why it matters
Guidance raise signals improved earnings outlook, but margin pressure from higher costs remains a risk.
Market read
Earnings guidance update is the primary catalyst for ZBH's near‑term price action.
What to watch
Potential supply‑chain disruptions in China and ongoing sales‑force transition may delay the upside.
Background
Zimmer Biomet reported Q3 2026 results, noting a decline in knee sales but growth in hips and technology, and raised its 2026 guidance.
Ticker impact
ZBH disclosed Q3 2026 earnings with raised guidance for hip growth and outlined 2027 outlook.
likely upward pressure as investors price in higher hip growth and improved 2027 outlook
Management highlighted double‑digit growth in hips and technology segments while acknowledging knee weakness, indicating a net positive earnings outlook.
Market effects
Positive guidance may lift the broader orthopedics and med‑tech sector.
U.S. med‑tech stocks could see modest gains.
Limited to investors tracking U.S. healthcare equipment makers.
Counterpoint
Knee segment weakness and higher manufacturing costs could offset hip growth, keeping the stock flat.
Key entities
- ExecutiveIvan Tornos
CEO of Zimmer Biomet providing guidance commentary.


